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Fatty acids do not initiate insulin release in the absence of glucose, but they potentiate glucose-induced insulin secretion (GSIS) upon acute exposure. Their mechanisms of action are, however, incompletely understood. The discovery of GPR40 as a G-protein--coupled receptor highly expressed in pancreatic β-cells and activated by long-chain fatty acids ([@r1]--[@r4]) has enabled the identification of a novel mechanism of action of fatty acids on insulin secretion. Loss of function of GPR40 via small interfering RNA ([@r2],[@r5]--[@r7]), antisense oligonucleotides ([@r8]), pharmacological inhibitors ([@r9]), or gene deletion in the mouse ([@r10],[@r11]) partially suppresses fatty acid potentiation of GSIS in vitro. We ([@r10]) and others ([@r11]) have shown that whole-body GPR40 knockout (KO) mice have normal glucose tolerance and unaltered insulin secretion in response to glucose in vivo and in vitro, but that isolated islets from these mice secrete less insulin in response to fatty acids. Furthermore, insulin secretion induced by Intralipid in vivo is reduced in GPR40 KO mice, demonstrating a physiological role for GPR40 in fatty acid--potentiation of GSIS ([@r10]).

GPR40 has received considerable attention as a potential therapeutic target in type 2 diabetes ([@r12]--[@r15]). Surprisingly, whether an agonist or antagonist should be developed as a therapeutic agent remains debated ([@r13],[@r15]). This uncertainty stems, in part, from conflicting reports regarding the role of GPR40 in β-cell function ([@r10],[@r11]). Steneberg et al. ([@r11]) found that islets isolated from GPR40 KO mice were protected from the inhibitory effects of prolonged fatty acid exposure on GSIS, in contrast to our findings in a different line of GPR40 KO mice ([@r10]) and a recent study using GPR40 agonists ([@r16]). Steneberg et al. ([@r11]) further showed that GPR40 KO mice were protected from high-fat diet (HFD)-induced insulin resistance, glucose intolerance, and hepatic steatosis. Given these discrepancies and the importance of determining whether an agonist or antagonist approach should be pursued for drug development, the present study was designed to test the hypothesis that GPR40 contributes to the enhancement of insulin secretion after HFD. Specifically, we sought to examine whether GPR40 KO mice are more susceptible to HFD-induced hyperglycemia and, if so, whether this is due to changes in insulin secretion in vivo or associated with changes in the expression of genes controlling fatty acid metabolism in islets.

RESEARCH DESIGN AND METHODS
===========================

Reagents were from the following sources: 50% dextrose was from McKesson Canada (Montréal, Canada), 0.9% saline was from Baxter (Mississauga, Canada), and Intralipid was from Fresenius Kabi (Uppsala, Sweden). All other reagents were from Sigma (St. Louis, MO) unless otherwise noted.

GPR40 KO mice were generated as described ([@r10]) and backcrossed to the C57BL/6 strain for more than seven generations at Amgen (San Francisco, CA). Animals were housed under controlled temperature conditions (21°C) and a 12-h light/dark cycle with free access to food and water. At 7 weeks of age, male GPR40 KO and wild-type (WT) littermates were fed either high-fat (60% fat, 16% protein, and 24% carbohydrate on a caloric basis \[\#F3282; Bioserv Diets, Frenchtown, NJ\]) or regular (23% fat, 17% protein, and 60% carbohydrates on a caloric basis \[\#2018; Harlan Teklad, Madison, WI\]) diet. Mice were housed individually, and body weight and food intake were determined weekly. All procedures using animals were approved by the institutional committee for the protection of animals at the Centre Hospitalier de l\'Université de Montréal.

Assessment of glucose homeostasis and insulin secretion.
--------------------------------------------------------

Fasting blood glucose was measured weekly. Oral glucose tolerance was assessed in overnight-fasted animals after administration of 1 g/kg glucose by gavage ([@r10]). Insulin tolerance was measured in 5-h fasted animals after intraperitonial administration of 1 unit/kg human insulin ([@r10]). For measurements of insulin secretion in vivo, a catheter was inserted into the right jugular vein under general anesthesia. Insulin secretion in response to intravenous glucose (0.5 g/kg) or Intralipid (100 μl of a 20% solution preceded by 30 units of heparin) was measured as described ([@r10]).

Tissue harvesting and histology.
--------------------------------

Mice were killed after 12 weeks of diet, and islets were isolated as described ([@r10]). Livers were snap-frozen in liquid nitrogen, embedded in OCT, prefrozen in anhydrous ethyl alcohol (100% ethanol), and stained with Oil Red O.

Gene expression studies.
------------------------

Total RNA was extracted from ∼150 islets, and RT-PCR was carried out using the QuantiTect SYBR Green PCR kit (Qiagen) as described ([@r17]). Results are expressed as the ratio of target mRNA to β-actin mRNA and normalized to the levels in islets from regular diet--fed WT mice, arbitrarily set as 1.

Analytical measurements.
------------------------

Plasma glucose and fatty acid levels were measured enzymatically (Wako Chemicals, Neuss, Germany). Plasma insulin was measured using a mouse ELISA kit (Alpco Diagnostics, Salem, NH).

Expression of data and statistics.
----------------------------------

Data are expressed as means ± SE. Intergroup comparisons were performed by ANOVA with post hoc adjustments for 2-by-2 comparisons or Student\'s *t* test where appropriate. *P* \< 0.05 was considered significant. In [Table 1](#t1){ref-type="table"} and [Fig. 3](#f3){ref-type="fig"}, glucose clearance and insulin secretion are expressed as the area under the curve, calculated above basal values, and expressed as arbitrary units.

RESULTS AND DISCUSSION
======================

Metabolic characteristics of GPR40 KO mice on a C57BL/6 background.
-------------------------------------------------------------------

Seven-week-old GPR40 KO mice on a C57BL/6 background had body weight similar to that of their WT littermates (22.5 ± 0.9 vs. 21.6 ± 0.9 g; *n* = 10 for each; *P* = NS) but showed fasting hyperglycemia (135.8 ± 5.3 vs. 115.4 ± 4.1 mg/dl; *n* = 19--22 per group; *P* \< 0.05; [Fig. 1*A*](#f1){ref-type="fig"}). Glucose and insulin tolerance were similar in GPR40 KO and WT mice at 7 weeks of age (supplementary Fig. S1, available in an online appendix at <http://dx.doi.org/10.2337/db08-0553>). Thus, on a pure C57BL/6 background, deletion of GPR40 leads to fasting hyperglycemia despite normal glucose and insulin tolerance, suggesting that GPR40 contributes to the maintenance of blood glucose levels during fasting. In the fasting state, circulating levels of fatty acids increase and the β-cell uses fatty acids as its main energy source, with a corresponding increase in fatty acid oxidation ([@r18]). Our results therefore suggest that GPR40-mediated fatty acid signaling contributes to the maintenance of basal insulin secretion---and thereby normoglycemia---during fasting.

Effects of HFD on glucose and insulin tolerance in GPR40 KO mice.
-----------------------------------------------------------------

Body weight, fat pad weight (white and brown adipose tissue), and food intake increased to similar levels in GPR40 KO and WT mice under HFD ([Table 1](#t1){ref-type="table"}). As expected, WT mice developed fasting hyperglycemia after 8 weeks of HFD. Fasting blood glucose increased earlier in GPR40 KO mice during the course of the HFD ([Fig. 1*B*](#f1){ref-type="fig"}). Thus, after 3 weeks on diet, blood glucose levels of the KO mice on HFD were significantly higher than those on regular diet (123.8 ± 5.2 vs. 101.9 ± 5.8 mg/dl; *n* = 8--11 per group; *P* \< 0.006), whereas WT mice on HFD and regular diet had similar blood glucose values (102.5 ± 3.5 vs. 93.3 ± 1.7 mg/dl, *n* = 10--11 per group; *P* \> 0.08). Both GPR40 KO and WT animals were hyperglycemic after 8 weeks of HFD. Oral and intravenous glucose tolerance were impaired to a similar extent in WT and KO mice after HFD ([Fig. 2*A*](#f2){ref-type="fig"} and [Table 1](#t1){ref-type="table"}) compared with mice on regular diet (supplementary Fig. S2A). Similarly, the glucose-lowering effect of insulin was reduced to the same extent in both genotypes on HFD ([Fig. 2*B*](#f2){ref-type="fig"}) compared with mice on regular diet (supplementary Fig. S2*B*). Liver steatosis developed in all animals examined of both genotypes under HFD ([Fig. 2*C*](#f2){ref-type="fig"}). Thus, GPR40 KO mice on a C57BL/6 background have fasting hyperglycemia that is further aggravated during HFD. Furthermore, HFD in both GPR40 KO mice and their WT littermates is associated with insulin resistance and glucose intolerance. Although we have not performed euglycemic-hyperinsulinemic clamps to directly measure insulin sensitivity, the observed decrease in the glucose-lowering effects of insulin, combined with the presence of liver steatosis, indicate that GPR40 KO mice were not protected from the development of insulin resistance during HFD. We suspect that the discrepancies between our results and those of Steneberg et al. ([@r11]) might be related to the genetic background of the mice, an important determinant of susceptibility to glucose intolerance ([@r19]). The mice used by Steneberg et al. ([@r11]) were of a mixed background as opposed to the C57BL/6 background used in the present study.

Effects of HFD on insulin secretion in GPR40 KO mice.
-----------------------------------------------------

To examine whether GPR40 plays a role in insulin secretion after HFD, we measured insulin release in response to glucose and Intralipid after 10 and 11 weeks, respectively, of HFD or regular diet. Insulin secretion in response to intravenous glucose was similar in regular diet--fed GPR40 KO and WT mice ([Fig. 3*A*, *C*, *D*](#f3){ref-type="fig"}). After administration of HFD, the second-phase insulin secretion to intravenous glucose was greatly enhanced in WT mice ([Fig. 3*B* and *D*](#f3){ref-type="fig"}), and this increase was significantly blunted in GPR40 KO mice ([Fig. 3*B* and *D*](#f3){ref-type="fig"}). These results suggest that GPR40 becomes rate-limiting for GSIS after HFD. These findings are consistent with the observation that enhancement of intracellular lipid signaling plays a role in β-cell compensation for insulin resistance ([@r20]). Interestingly, the marked differences in GSIS between GPR40 KO and WT mice after HFD were not accompanied by changes in glucose clearance, which is in keeping with the notion that glucose clearance after an intravenous load in mice is mostly determined by insulin-independent mechanisms ([@r21],[@r22]).

As shown in [Fig. 3*E* and *G*](#f3){ref-type="fig"}, GPR40 KO mice on a C57BL/6 background have reduced insulin secretion in response to Intralipid, as previously shown in mice on a mixed background ([@r23]). Thus, first-phase insulin secretion was lower in GPR40 KO mice in response to Intralipid compared with WT littermates (6.72 ± 1.59 vs. 11.10 ± 1.47 AU; *n* = 6--7; *P* \< 0.05). After 11 weeks on HFD, WT mice had a markedly increased response to intravenous Intralipid compared with that of regular diet--fed mice ([Fig. 3*F*--*H*](#f3){ref-type="fig"}). In contrast, the increase in first-phase insulin release in response to Intralipid after HFD was markedly reduced in GPR40 KO mice ([Fig. 3*F*--*H*](#f3){ref-type="fig"}). These findings show that GPR40 not only plays a role in insulin secretion in response to fatty acids under basal conditions but is essential for the β-cell to mount a compensatory increase in insulin secretion in response to both glucose and fatty acids in the face of HFD-induced insulin resistance.

Effects of HFD on gene expression in GPR40 KO mice.
---------------------------------------------------

To gain insight into the molecular basis for the role of GPR40 in insulin secretion, mRNA levels of genes involved in fatty acid transport and metabolism were measured in islets from GPR40 KO and WT mice after HFD or regular diet ([Table 1](#t1){ref-type="table"}). GPR120 is another receptor for long-chain fatty acids expressed in enteroendocrine cells ([@r23]). We found GPR120 mRNA to be expressed in isolated mouse islets, although its expression did not increase in compensation for the absence of GPR40 in GPR40 KO islets ([Table 1](#t1){ref-type="table"}). CD36 is a fatty acid transport protein that plays an important role in fatty acid uptake and fatty acid potentiation of GSIS ([@r24]). Carnitine palmitoyl transferase-1 (CPT-1) catalyzes the rate-limiting step in fatty acid oxidation, i.e., transport of long-chain acyl-CoAs across the mitochondrial membrane ([@r25]). GPR40 KO mice on regular diet displayed an approximate five and sevenfold increase in islet CD36 and CPT-1 mRNA expression, respectively, compared with WT islets ([Table 1](#t1){ref-type="table"}), suggesting an attempt to compensate for the absence of GPR40 by enhancing fatty acid transport and intracellular metabolism. Although expression of neither CD36 nor CPT-1 was significantly affected by HFD in WT animals, in KO islets the increase in CD36 and CPT1 gene expression was markedly reduced by HFD. This suggests that enhanced expression of CD36 and CPT1 perhaps contributes to the maintenance of normal glucose tolerance despite the absence of GPR40 under basal conditions, but that the absence of such an increase under HFD results in an inability of the mice to sustain normal GSIS.

GPR40 KO mice on a C57BL/6 background have fasting hyperglycemia and are not protected from HFD-induced insulin resistance, and GPR40 is implicated not only in insulin secretion in response to fatty acids but also in GSIS after HFD. These findings suggest that the mechanisms by which the β-cell mounts a compensatory response to HFD-induced insulin resistance involve, at least in part, signaling through GPR40. As such, our results raise doubts on the validity of a therapeutic approach based on GPR40 antagonism for the treatment of type 2 diabetes.
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![Fasting blood glucose levels of GPR40 KO and WT mice before (*A*) and during (*B*) feeding a high-fat (HF) or regular diet (RD). \**P* \< 0.05.](zdb0090854290001){#f1}

![*A*: Glucose levels during oral glucose tolerance tests (OGTTs) after 8 weeks of HFD; *n* = 10--11 mice per group. *B*: Glucose levels during intraperitoneal insulin tolerance tests (IPITTs) after 9 weeks of HFD; *n* = 8--10 mice per group. *C*: Oil Red O staining of liver sections of KO and WT mice fed regular diet (RD) or HFD. Images are representative of 3--4 animals in each group. (Please see <http://dx.doi.org/10.2337/db08-0553> for a high-quality digital representation of this figure.)](zdb0090854290002){#f2}

###### 

*A* and *B*: Insulin levels in response to intravenous glucose after 10 weeks of regular diet (RD) (*A*) or HFD (*B*). *C* and *D*: Area under the curve (AUC) for insulin over the first 10 min (*C*) and from 10--60 min (*D*) following glucose injection. Values are expressed as means ± SE of 8--10 mice per group. *E* and *F*: Insulin levels in response to intravenous Intralipid after 11 weeks of regular diet (*E*) or HFD (*F*). *G* and *H*: Area under the curve for insulin for the first 10 min (*G*) and from 10--60 min (*H*) following Intralipid injection. Values are expressed as means ± SE of 6--8 mice per group. \**P* \< 0.
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###### 

Metabolic parameters of GPR40 knockout and wild-type mice fed regular diet or HFD and gene expression levels in islets

                                         WT-RD            WT-HFD                                            KO-RD                                       KO-HFD
  -------------------------------------- ---------------- ------------------------------------------------- ------------------------------------------- -------------------------------------------------
  Weight gain (g)                        6.1 ± 0.7        14.5 ± 1.3[\*](#t1fn1){ref-type="table-fn"}       5.6 ± 0.8                                   11.5 ± 1.9[\*](#t1fn1){ref-type="table-fn"}
  Food intake (kcal · g^−1^ · day^−1^)   0.58 ± 0.02      0.64 ± 0.05                                       0.61 ± 0.02                                 0.62 ± 0.05
  Subcutaneous fat (g)                   0.19 ± 0.02      1.12 ± 0.13[\*](#t1fn1){ref-type="table-fn"}      0.11 ± 0.02                                 0.84 ± 0.16[\*](#t1fn1){ref-type="table-fn"}
  Infra-renal fat (g)                    0.04 ± 0.00      0.39 ± 0.07[\*](#t1fn1){ref-type="table-fn"}      0.03 ± 0.00                                 0.29 ± 0.06[\*](#t1fn1){ref-type="table-fn"}
  Brown adipose tissue (g)               0.07 ± 0.01      0.15 ± 0.02[\*](#t1fn1){ref-type="table-fn"}      0.11 ± 0.01                                 0.20 ± 0.05[\*](#t1fn1){ref-type="table-fn"}
  AUC~glucose~ OGTT week 8               11,715 ± 1,104   18,517 ± 1,612[\*](#t1fn1){ref-type="table-fn"}   13,183 ± 1,496                              17,847 ± 997[\*](#t1fn1){ref-type="table-fn"}
  AUC~glucose~ IVGTT week 10             12,613 ± 1,491   19,024 ± 2,445[\*](#t1fn1){ref-type="table-fn"}   10,949 ± 1,049                              15,348 ± 3,189[\*](#t1fn1){ref-type="table-fn"}
  GPR40 mRNA                             1.0 ± 0.2        0.4 ± 0.2                                         ND                                          ND
  GPR120 mRNA                            1.0 ± 0.4        0.7 ± 0.3                                         1.3 ± 0.4                                   0.7 ± 0.2
  CD36 mRNA                              1.0 ± 0.3        1.4 ± 0.2                                         5.2 ± 0.4[†](#t1fn2){ref-type="table-fn"}   2.6 ± 0.5
  CPT-1 mRNA                             1.0 ± 0.2        0.9 ± 0.2                                         6.7 ± 1.0[†](#t1fn2){ref-type="table-fn"}   1.1 ± 0.2

Data are means ± SE. *n* = 9--12 animals per group. AUC, area under the curve; IVGTT, intravenous glucose tolerance test; ND, not determined; OGTT, oral glucose tolerance test; RD, regular diet.

*P* \< 0.05 vs. RD;

*P* \< 0.05 vs. WT.
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